↓ Skip to main content

Wiley Online Library

Umbilical cord mesenchymal stem cells for COVID ‐19 acute respiratory distress syndrome: A double‐blind, phase 1/2a, randomized controlled trial

Overview of attention for article published in Stem Cells Translational Medicine, January 2021
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#1 of 1,330)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news
90 news outlets
blogs
6 blogs
twitter
70 tweeters
facebook
2 Facebook pages
reddit
2 Redditors

Readers on

mendeley
33 Mendeley
Title
Umbilical cord mesenchymal stem cells for COVID ‐19 acute respiratory distress syndrome: A double‐blind, phase 1/2a, randomized controlled trial
Published in
Stem Cells Translational Medicine, January 2021
DOI 10.1002/sctm.20-0472
Pubmed ID
Authors

Giacomo Lanzoni, Elina Linetsky, Diego Correa, Shari Messinger Cayetano, Roger A. Alvarez, Dimitrios Kouroupis, Ana Alvarez Gil, Raffaella Poggioli, Phillip Ruiz, Antonio C. Marttos, Khemraj Hirani, Crystal A. Bell, Halina Kusack, Lisa Rafkin, David Baidal, Andrew Pastewski, Kunal Gawri, Clarissa Leñero, Alejandro M. A. Mantero, Sarah W. Metalonis, Xiaojing Wang, Luis Roque, Burlett Masters, Norma S. Kenyon, Enrique Ginzburg, Xiumin Xu, Jianming Tan, Arnold I. Caplan, Marilyn K. Glassberg, Rodolfo Alejandro, Camillo Ricordi

Twitter Demographics

The data shown below were collected from the profiles of 70 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 33 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 33 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 15%
Professor 4 12%
Student > Bachelor 4 12%
Student > Doctoral Student 4 12%
Other 2 6%
Other 8 24%
Unknown 6 18%
Readers by discipline Count As %
Medicine and Dentistry 14 42%
Biochemistry, Genetics and Molecular Biology 5 15%
Nursing and Health Professions 2 6%
Pharmacology, Toxicology and Pharmaceutical Science 2 6%
Computer Science 1 3%
Other 3 9%
Unknown 6 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 756. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 February 2021.
All research outputs
#12,705
of 17,102,659 outputs
Outputs from Stem Cells Translational Medicine
#1
of 1,330 outputs
Outputs of similar age
#818
of 378,603 outputs
Outputs of similar age from Stem Cells Translational Medicine
#1
of 65 outputs
Altmetric has tracked 17,102,659 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,330 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.9. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 378,603 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 65 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.